The GLASSIA BAL Immuno Study is further evaluating the safety and effectiveness of an investigational drug called GLASSIA, also known as alpha1-proteinase inhibitor (human). The effects of this investigational drug will be assessed as augmentation therapy for 25 weeks in adults 18 years of age and older with emphysema caused by alpha-1 deficiency.
Augmentation therapy consists of weekly IV infusions of alpha1-proteinase inhibitor (A1-PI) protein from the blood plasma of healthy human donors to augment (increase) the alpha-1 levels circulating in the blood and lungs of people diagnosed with emphysema.
The GLASSIA BAL Immuno Study may be appropriate for those who meet the following criteria:
This clinical research study is currently recruiting in the US and Canada.
Participants in the GLASSIA BAL Immuno Study will need to:
Additional bronchoalveolar lavage (BAL) testing may be available; no additional visits will be needed for this testing.
This clinical research study is testing an investigational drug. You may qualify for this clinical research study.
Learn more about emphysema caused by alpha-1 deficiency.